<?xml version="1.0" encoding="UTF-8"?>
<ref id="pmed.1002882.ref075">
 <label>75</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Podany</surname>
   <given-names>AT</given-names>
  </name>, 
  <name>
   <surname>Bao</surname>
   <given-names>Y</given-names>
  </name>, 
  <name>
   <surname>Swindells</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Chaisson</surname>
   <given-names>RE</given-names>
  </name>, 
  <name>
   <surname>Andersen</surname>
   <given-names>JW</given-names>
  </name>, 
  <name>
   <surname>Mwelase</surname>
   <given-names>T</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention</article-title>. 
  <source>Clin Infect Dis</source>. 
  <year>2015</year>;
  <volume>61</volume>(
  <issue>8</issue>):
  <fpage>1322</fpage>â€“
  <lpage>7</lpage>. 
  <pub-id pub-id-type="doi">10.1093/cid/civ464</pub-id>
  <?supplied-pmid 26082504?>
  <pub-id pub-id-type="pmid">26082504</pub-id>
 </mixed-citation>
</ref>
